| Liver carcinoma
Lenvima vs Imfinzi
Side-by-side clinical, coverage, and cost comparison for liver carcinoma.Deep comparison between: Lenvima vs Imfinzi with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsImfinzi has a higher rate of injection site reactions vs Lenvima based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Imfinzi but not Lenvima, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Lenvima
Imfinzi
At A Glance
Oral
Once daily
Multi-kinase inhibitor
IV infusion
Every 2 to 4 weeks
PD-L1 antagonist
Indications
- Differentiated Thyroid Gland Carcinoma
- Renal Cell Carcinoma
- Liver carcinoma
- Endometrial Carcinoma
- Non-Small Cell Lung Carcinoma
- Small cell carcinoma of lung
- Biliary Tract Cancer
- Liver carcinoma
- Endometrial Carcinoma
- Carcinoma of bladder
- Stomach Carcinoma
- Gastroesophageal junction cancer
Dosing
Differentiated Thyroid Gland Carcinoma 24 mg orally once daily until disease progression or unacceptable toxicity.
Renal Cell Carcinoma (first-line, with pembrolizumab) 20 mg orally once daily in combination with pembrolizumab 200 mg IV infusion over 30 minutes every 3 weeks until disease progression or unacceptable toxicity or up to 2 years.
Renal Cell Carcinoma (previously treated, with everolimus) 18 mg orally once daily in combination with everolimus 5 mg orally once daily until disease progression or unacceptable toxicity.
Liver carcinoma 12 mg orally once daily for patients >=60 kg or 8 mg orally once daily for patients <60 kg, until disease progression or unacceptable toxicity.
Endometrial Carcinoma 20 mg orally once daily in combination with pembrolizumab 200 mg IV infusion over 30 minutes every 3 weeks until unacceptable toxicity or disease progression.
Resectable NSCLC Neoadjuvant: 1,500 mg IV every 3 weeks in combination with chemotherapy for up to 4 cycles prior to surgery (or 20 mg/kg if weight <30 kg). Adjuvant: 1,500 mg IV every 4 weeks as a single agent for up to 12 cycles after surgery (or 20 mg/kg if weight <30 kg).
Unresectable Stage III NSCLC 1,500 mg IV every 4 weeks or 10 mg/kg every 2 weeks as a single agent until disease progression or unacceptable toxicity (maximum 12 months) (or 10 mg/kg every 2 weeks if weight <30 kg).
Metastatic NSCLC 1,500 mg IV in combination with tremelimumab-actl 75 mg and platinum-based chemotherapy every 3 weeks for 4 cycles, then 1,500 mg every 4 weeks as a single agent with pemetrexed maintenance for non-squamous (or 20 mg/kg and 1 mg/kg tremelimumab-actl if weight <30 kg).
Limited Stage SCLC 1,500 mg IV every 4 weeks as a single agent until disease progression or unacceptable toxicity (maximum 24 months) (or 20 mg/kg if weight <30 kg).
Extensive Stage SCLC 1,500 mg IV every 3 weeks in combination with etoposide and carboplatin or cisplatin for 4 cycles, then 1,500 mg every 4 weeks as a single agent until disease progression (or 20 mg/kg if weight <30 kg).
Biliary Tract Cancer 1,500 mg IV every 3 weeks in combination with gemcitabine and cisplatin for up to 8 cycles, then 1,500 mg every 4 weeks as a single agent until disease progression (or 20 mg/kg if weight <30 kg).
Unresectable Hepatocellular Carcinoma 1,500 mg IV in combination with a single dose of tremelimumab-actl 300 mg at Cycle 1/Day 1, followed by 1,500 mg every 4 weeks as a single agent until disease progression (or 20 mg/kg and 4 mg/kg tremelimumab-actl if weight <30 kg).
dMMR Endometrial Carcinoma 1,120 mg IV in combination with carboplatin and paclitaxel every 3 weeks for 6 cycles, followed by 1,500 mg every 4 weeks as a single agent until disease progression (or 15 mg/kg followed by 20 mg/kg if weight <30 kg).
Muscle Invasive Bladder Cancer Neoadjuvant: 1,500 mg IV in combination with gemcitabine and cisplatin every 3 weeks for 4 cycles prior to surgery (or 20 mg/kg if weight <30 kg). Adjuvant: 1,500 mg IV every 4 weeks as a single agent for up to 8 cycles after surgery (or 20 mg/kg if weight <30 kg).
Resectable Gastric/Gastroesophageal Junction Adenocarcinoma Neoadjuvant: 1,500 mg IV every 4 weeks with FLOT for up to 2 cycles prior to surgery (or 20 mg/kg if weight <30 kg). Adjuvant: 1,500 mg IV every 4 weeks with FLOT for up to 2 cycles, followed by 1,500 mg as a single agent every 4 weeks for up to 10 cycles (or 20 mg/kg if weight <30 kg).
Contraindications
—
—
Adverse Reactions
Most common (>=20%) Hypertension, fatigue, diarrhea, arthralgia/myalgia, decreased appetite, decreased weight, nausea, stomatitis, headache, vomiting, proteinuria, palmar-plantar erythrodysesthesia syndrome, abdominal pain, dysphonia, hypothyroidism, hemorrhagic events, rash, musculoskeletal pain.
Serious Hepatic encephalopathy, hepatic failure, cardio-respiratory arrest, sepsis, myocardial infarction, pneumonitis, acute kidney injury, renal failure, dehydration, thrombocytopenia, dyspnea, anemia.
Postmarketing Pancreatitis, impaired wound healing, cholecystitis, nephrotic syndrome, arterial aneurysms/dissections/rupture.
Most common (>=10%) Nausea, fatigue, cough, pneumonitis, rash, diarrhea, decreased appetite, musculoskeletal pain, constipation, dyspnea, upper respiratory tract infections, pyrexia, pruritus, headache, vomiting, abdominal pain, hypothyroidism, peripheral neuropathy, alopecia, insomnia
Serious Pneumonitis, pneumonia, hepatitis, colitis, myocarditis, nephritis, endocrinopathies, infusion-related reactions, exfoliative dermatologic conditions
Postmarketing Not specified in label
Pharmacology
Lenvatinib is a multi-kinase inhibitor that inhibits VEGFR1, VEGFR2, and VEGFR3 kinase activities as well as FGFR1-4, PDGFRA, KIT, and RET, suppressing pathogenic angiogenesis and tumor growth; in combination with pembrolizumab or everolimus, it demonstrates enhanced antiangiogenic and antitumor activity.
Durvalumab is a human IgG1 kappa monoclonal antibody that binds to PD-L1 and blocks the interaction of PD-L1 with PD-1 and CD80, releasing the inhibition of immune responses without inducing antibody-dependent cell-mediated cytotoxicity.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Lenvima
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
Imfinzi
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Lenvima
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (4/8)
Imfinzi
- Covered on 4 commercial plans
- PA (2/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Lenvima
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (2/3)
Imfinzi
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Lenvima.
No savings programs available for Imfinzi.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
LenvimaView full Lenvima profile
ImfinziView full Imfinzi profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.